Sirius is a San Diego & Shanghai based clinical-stage biotech dedicated to developing the clinical and commercial value of siRNA therapies. We focus on cardiometabolic diseases (Lp(a) siRNA in ph2), obesity (INHBE in IND enabling), and anti-coagulation (FXI siRNA in ph2, 50:50 co-development with CRISPR Therapeutics) to transform the current standard of care for chronic diseases. Sirius' pre-clinical ex-hepatic programs focus on adipose, muscle, heart, and kidney tissues. Our clinical data portfolio is global, generated from sites in Australia, China, and Europe. Sirius was founded by OrbiMed and a group of scientists including Dr. Curt Bradshaw, ex-CSO of Arrowhead.